8-K: Current report filing
Published on October 30, 1996
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 30, 1996
-----------------
Merrill Lynch & Co., Inc.
-------------------------------
(Exact name of Registrant as specified in its charter)
Delaware 1-7182 13-2740599
- -------------------------------------------------------------------------------
(State or other (Commission (I.R.S. Employer
jurisdiction of File Number) Identification No.)
incorporation)
World Financial Center, North Tower, New York, New York 10281-1220
- -------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (212) 449-1000
-----------------
- -------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
Item 5. Other Events
- ------ -------------
Exhibits are filed herewith in connection with the Registration
Statement on Form S-3 (File No. 33-65135) filed by Merrill Lynch & Co., Inc.
("ML & Co.") with the Securities and Exchange Commission covering Senior Debt
Securities issuable under an indenture dated as of April 1, 1983, as amended and
restated, between ML & Co. and The Chase Manhattan Bank, formerly known as
Chemical Bank (successor by merger to Manufacturers Hanover Trust Company) (the
"Indenture"). ML & Co. will issue $15,000,000 principal amount of
Healthcare/Biotechnology Portfolio Market Index Target-Term Securities due
October 31, 2001 under the Indenture. The exhibits consist of the form of
Securities and an opinion of counsel relating thereto.
Item 7. Financial Statements, Pro Forma Financial Information
- ------- -----------------------------------------------------
and Exhibits
------------
EXHIBITS
(4) Instruments defining the rights of
security holders, including indentures.
Form of Merrill Lynch & Co., Inc.'s
Healthcare/Biotechnology Portfolio Market
Index Target-Term Securities due October
31, 2001.
(5) & (23) Opinion re: legality; consent of
counsel.
Opinion of Brown & Wood LLP relating to
the Healthcare/Biotechnology Portfolio
Market Index Target-Term Securities due
October 31, 2001 (including consent for
inclusion of such opinion in this report
and in Merrill Lynch & Co., Inc.'s
Registration Statement relating to such
Securities).
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereto duly authorized.
MERRILL LYNCH & CO., INC.
-------------------------
(Registrant)
By: /s/ Theresa Lang
---------------------
Theresa Lang
Treasurer
Date: October 30, 1996
3
Exhibit Index
Exhibit No. Description Page
- ----------- -----------
(4) Instruments defining the rights of
security holders, including
indentures.
Form of Merrill Lynch & Co., Inc.'s
Healthcare/Biotechnology Portfolio Market
Index Target-Term Securities due October 31,
2001.
(5) & (23) Opinion re: legality; consent of
counsel.
Opinion of Brown & Wood LLP relating to the
Healthcare/Biotechnology Portfolio Market
Index Target-Term Securities due October 31,
2001 (including consent for inclusion of
such opinion in this report and in Merrill
Lynch & Co., Inc.'s Registration Statement
relating to such Securities).